Search Results - "MILLIKAN, R. E"

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies by Matrana, M.R, Duran, C, Shetty, A, Xiao, L, Atkinson, B.J, Corn, P, Pagliaro, L.C, Millikan, R.E, Charnsangave, C, Jonasch, E, Tannir, N.M

“…Abstract Aim The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory…”
Get full text

Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-α: association of pretreatment serum levels with survival by Montero, A.J., Diaz-Montero, C.M., Millikan, R.E., Liu, J., Do, K.-A., Hodges, S., Jonasch, E., McIntyre, B.W., Hwu, P., Tannir, N.

“…To correlate serum cytokine and angiogenic factor (CAF) levels with overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with interferon-α…”
Get full text

Evaluating multiple treatment courses in clinical trials by Thall, Peter F., Millikan, Randall E., Sung, Hsi-Guang

“…In oncology, a patient's treatment often involves multiple courses of chemotherapy. The most common medical practice in choosing treatments for successive…”
Get full text

Chemotherapy of advanced prostatic carcinoma by Millikan, R E

“…Metastatic prostate cancer remains incurable. Historically, therapy options for patients with nonlocalized disease have been limited to hormonal therapy and…”
Get more information

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer by ELLERHORST, J. A, TU, S.-M, AMATO, R. J, FINN, L, MILLIKAN, R. E, PAGLIARO, L. C, JACKSON, A, LOGOTHETIS, C. J

“…Two distinct regimens of weekly chemotherapy for hormone-refractory prostate cancer were combined in an alternating schedule and tested in a Phase II trial to…”
Get full text

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours by FIZAZI, K, PROW, D. M, PAGLIARO, L. C, LOGOTHETIS, C. J, AMATO, R. J, DO, K-A, WANG, X, FINN, L, KIM, J, DALIANI, D, PAPANDREOU, C. N, TU, S-M, MILLIKAN, R. E

“…Only about half of patients with a poor-prognosis non-seminomatous germ-cell tumours can achieve a cure. The aim of this phase II study was to assess the…”
Get full text

Bladder Cancer Predisposition: A Multigenic Approach to DNA-Repair and Cell-Cycle–Control Genes by Wu, Xifeng, Gu, Jian, Grossman, H. Barton, Amos, Christopher I., Etzel, Carol, Huang, Maosheng, Zhang, Qing, Millikan, Randal E., Lerner, Seth, Dinney, Colin P., Spitz, Margaret R.

“…The candidate-gene approach in association studies of polygenic diseases has often yielded conflicting results. In this hospital-based case-control study with…”
Get full text

Phase II trial of 5‐fluorouracil, interferon‐α and continuous infusion interleukin‐2 for patients with metastatic renal cell carcinoma by Ellerhorst, Julie A., Sella, Avishay, Amato, Robert J., Tu, Shi‐Ming, Millikan, Randall E., Finn, Laury D., Banks, Marie, Logothetis, Christopher J.

“…BACKGROUND This study was designed to evaluate the efficacy and toxicity of the combination of 5‐fluorouracil, interferon‐α, and interleukin‐2 for patients…”
Get full text

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial by Tu, Shi-Ming, Millikan, Randall E, Mengistu, Bayabel, Delpassand, Ebrahim S, Amato, Robert J, Pagliaro, Lance C, Daliani, Danai, Papandreou, Christos N, Smith, Terry L, Kim, Jeri, Podoloff, Donald A, Logothetis, Christopher J

“…Prostate carcinoma is linked to osteoblasticmetastasis. We therefore investigated the value of bonetargetedconsolidation therapy in selected patients with…”
Get full text

Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer by TU, S.-M, PAGLIARO, L. C, BANKS, M. E, AMATO, R. J, MILLIKAN, R. E, BUGAZIA, N. A, MADDEN, T, NEWMAN, R. A, LOGOTHETIS, C. J

“…In this study, we determined the maximum tolerated plasma concentration of suramin (within the predetermined study target range) when combined with doxorubicin…”
Get full text

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer by PAPANDREOU, Christos N, DALIANI, Danai D, KIM, Jeri, ADAMS, Julian, ELLIOTT, Peter, ESSELTINE, Dixie, PETRUSICH, Alexandria, DIERINGER, Pauline, PEREZ, Cherie, LOGOTHETIS, Christopher J, NIX, Darrell, HONG YANG, MADDEN, Timothy, XUEMEI WANG, PIEN, Christine S, MILLIKAN, Randall E, TU, Shi-Ming, PAGLIARO, Lance

“…To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5…”
Get full text

Prospects for Optimized Clinical Management of Bladder Cancer by Application of Phenotypic Markers by Millikan, Randall E., Logothetis, Christopher J.

Get full text

A Phase I/II study of strontium‐89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases by Pagliaro, Lance C., Delpassand, Ebrahim S., Williams, Dallas, Millikan, Randall E., Tu, Shi‐Ming, Logothetis, Christopher J.

“…BACKGROUND The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination…”
Get full text

Gemcitabine modulation of alkylator therapy : A Phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin by MILLIKAN, Randall E, PLUNKETT, William K, SMITH, Terry L, WILLIAMS, Dallas L, LOGOTHETIS, Christopher J

“…The authors investigated the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) associated with the addition of a biomodulating dose of gemcitabine…”
Get full text

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after progression during treatment with other targeted therapies by Matrana, M. R., Duran, C., Shetty, A., Xiao, L., Atkinson, B. J., Corn, P., Pagliaro, L. C., Millikan, R. E., Charnsangavej, C., Jonasch, E., Tannir, N. M.

Get full text

Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens by Thall, Peter F., Logothetis, Christopher, Pagliaro, Lance C., Wen, Sijin, Brown, Melissa A., Williams, Dallas, Millikan, Randall E.

“…Background Physicians typically switch therapies unless clinically relevant thresholds of response are observed, and treatments that produce high-quality…”
Get full text

Can we reliably identify patients for radical cystectomy without neoadjuvant chemotherapy? by Dickstein, R. J., Grossman, H. B., Pretzsch, S. M., Karam, J. A., Millikan, R. E., Dinney, C. P., Kamat, A. M.

“…Abstract only 258 Background: When neoadjuvant chemotherapy is administered prior to radical cystectomy in patients with muscle-invasive urothelial cancer, the…”
Get full text

The impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The M. D. Anderson Cancer Center experience by Lynch, S. P., Vu, T. T., Kamat, A. M., Grossman, H. B., Millikan, R. E., Dinney, C. P., Siefker-Radtke, A. O.

“…Abstract only…”
Get full text

Cytokines and angiogenic factors in metastatic renal cell cancer: Association of pretreatment serum levels with survival by Montero, A. J., Diaz-Montero, C. M., Liu, J., Do, K., Millikan, R. E., Tannir, N. M.

“…Abstract only e16036 Background: To correlate serum cytokine and angiogenic factor (CAF) levels and overall survival (OS) in metastatic renal cell cancer…”
Get full text

Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-[alpha]: association of pretreatment serum levels with survival by Montero, A J, Diaz-montero, C M, Millikan, R E, Liu, J, K.-a. Do, Hodges, S, Jonasch, E, Mcintyre, B W, Hwu, P, Tannir, N

“…Background: To correlate serum cytokine and angiogenic factor (CAF) levels with overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with…”
Get full text